Epigral Ltd

- For FY 2026, Epigral has a planned CAPEX of around Rs. 450 crore. - The company intends to primarily fund this CAPEX through internal accruals and debt, if required. - There is currently no plan for raising funds through Qualified Institutional Placements (QIPs) or equity. - Management emphasized a preference for ensuring smooth project execution and may borrow from banks if internal accruals alone are insufficient during peak CAPEX cycles. - No new equity fundraising or QIPs are planned at present; debt and internal funds remain the primary financing modes going forward.

- Planned CAPEX of around Rs. 450 crore for FY 2026 focused on expanding capacities in CPVC resin (addition of 75,000 tonnes to reach 1,50,000 tonnes) and Epichlorohydrin (expanding from 50,000 to 1,00,000 tonnes by H1 FY 2027). - Newly commissioned plants (CPVC, CPVC compound, chlorotoluene) expected to reach optimum utilization by end of FY 2026. - Minor debottlenecking CAPEX expected for chlor-alkali (caustic soda and chlorine integration) once operating at ~90% levels; no major chlor-alkali expansion planned currently. - New 100-acre land acquired for establishing a new value chain with new chemistry unrelated to current chlor-alkali; strategic project under Board consideration and approval, phases and capex yet to be finalized. - Financing primarily through internal accruals and possible bank debt; no QIPs planned for current CAPEX cycle.

- Epigral Limited expects a volume growth CAGR of **10% to 15% over the next 5 years** driven by capacity expansions. - Revenue growth is anticipated at **15% to 20% CAGR** over the next 4-5 years, supported by new CAPEX and increased volumes. - Key growth drivers include ramp-up of **CPVC resin and compound capacity**, **Epichlorohydrin (ECH)** expansion, and the newly commissioned **chlorotoluene plant**. - The company aims to increase revenue contribution from the Derivatives & Specialty business from **54% in FY25 to around 70%**. - The chlor-alkali integration with captive chlorine consumption is expected to improve, with target utilization at **80-90% by FY27**. - The firm is working on a new chemistry value chain on a **100-acre new site** for long-term growth beyond chlor-alkali derivatives. - Overall, the strategy emphasizes consistent growth through product diversification and capacity utilization improvements.

- Epigral targets consistent volume growth of 10-15% CAGR over the next five years, driven by CAPEX expansions in CPVC resin, Epichlorohydrin, and chlorotoluene plants. - Management expects 15-20% CAGR growth in revenue over the next 4-5 years, supported by increased capacity utilization and high-value product sales. - The FY’26 volume growth is expected to mainly come from ramp-up in CPVC and Epichlorohydrin production. - EBITDA margin guidance is around 25%, with recent margins at about 28%, considered sustainable given diversification. - PAT for FY‘25 rose 82% to Rs.357 crore, with expectations for continuing profit growth aligned with volume and value increase. - Long-term strategy involves developing new chemistry value chains at a new 100-acre site, which will further supplement growth beyond current plans. - Management remains on track with their five-year vision to double revenues from Rs.2,500 crore (FY25 base), though timing and exact targets may be adjusted based on market conditions.

The transcript does not explicitly mention the current or expected order book or pending orders for Epigral Limited. However, some relevant insights related to demand and capacity utilization can be summarized: - Volume growth expected at around 10% to 15% CAGR over the next 4-5 years, driven by capacity additions and ramp-up. - New plants like chlorotoluene, CPVC resin, and epichlorohydrin commissioned recently and in process of commercialization, with approvals expected within 6-8 months. - Capacity utilization of chlor-alkali plant expected to rise to around 85-90%. - Growth drivers include exports (especially agrochemical and pharma intermediates) and domestic demand. - Management indicated optimism on consistent demand growth but did not specify order book figures. In summary, the company is in an expansion and ramp-up phase, with growing volumes from recent CAPEX, but no explicit order book details were disclosed.